Insider Selling: Artivion (NYSE:AORT) CAO Sells $79,825.18 in Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 1,789 shares of Artivion stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $44.62, for a total transaction of $79,825.18. Following the completion of the sale, the chief accounting officer directly owned 144,862 shares of the company’s stock, valued at approximately $6,463,742.44. This trade represents a 1.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Amy Horton also recently made the following trade(s):

• On Thursday, November 13th, Amy Horton sold 3,482 shares of Artivion stock. The shares were sold at an average price of $45.86, for a total value of $159,684.52.

Artivion Stock Up 0.3%

Shares of AORT stock opened at $45.71 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04. The company’s fifty day moving average price is $42.69 and its 200-day moving average price is $36.18. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of -108.84 and a beta of 1.65.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The business’s revenue for the quarter was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Sell-side analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on AORT shares. JMP Securities raised their target price on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Stifel Nicolaus lifted their target price on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a report on Monday, September 29th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Finally, LADENBURG THALM/SH SH lowered Artivion from a “buy” rating to a “neutral” rating and increased their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.11.

Institutional Investors Weigh In On Artivion

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC increased its position in shares of Artivion by 50.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 22,141 shares of the company’s stock worth $937,000 after purchasing an additional 7,392 shares in the last quarter. Amundi purchased a new position in shares of Artivion in the 3rd quarter valued at approximately $297,000. Osterweis Capital Management Inc. grew its position in Artivion by 99.7% in the 3rd quarter. Osterweis Capital Management Inc. now owns 240,772 shares of the company’s stock valued at $10,194,000 after buying an additional 120,192 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Artivion by 235.5% in the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after acquiring an additional 313,446 shares during the period. Finally, iSAM Funds UK Ltd purchased a new stake in Artivion in the 3rd quarter valued at approximately $131,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.